Related Experiment Video
Updated: Jun 23, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response
Orsolya Papp1, Viktória Jordán1, Szabolcs Hetey1
1Turbine Simulated Cell Technologies, Budapest, Hungary.
Abstract:
Combination therapy is well established as a key intervention strategy for cancer treatment, with the potential to overcome monotherapy resistance and deliver a more durable efficacy. However, given the scale of unexplored potential target space and the resulting combinatorial explosion, identifying efficacious drug combinations is a critical unmet need that is still evolving. In this paper, we demonstrate a network biology-driven, simulation-based solution, the Simulated Cell™. Integration of omics data with a curated signaling network enables the accurate and interpretable prediction of 66,348 combination-cell line pairs obtained from a large-scale combinatorial drug sensitivity screen of 684 combinations across 97 cancer cell lines (BAC = 0.62, AUC = 0.7). We highlight drug combination pairs that interact with DNA Damage Response pathways and are predicted to be synergistic, and deep network insight to identify biomarkers driving combination synergy. We demonstrate that the cancer cell 'avatars' capture the biological complexity of their in vitro counterparts, enabling the identification of pathway-level mechanisms of combination benefit to guide clinical translatability.
Insights
Identifying effective cancer drug combinations is challenging. This study introduces Simulated Cell™, a network biology approach, to accurately predict synergistic drug pairs and their biomarkers, improving cancer treatment strategies.
Area of Science:
- Computational Biology
- Systems Biology
- Cancer Research
Background:
- Combination therapy offers improved cancer treatment efficacy over monotherapy by overcoming resistance.
- Identifying optimal drug combinations is a significant challenge due to the vast number of potential pairings.
Purpose of the Study:
- To develop and validate a network biology-driven simulation approach for predicting synergistic cancer drug combinations.
- To identify biomarkers associated with drug combination synergy and understand underlying mechanisms.
Main Methods:
- Utilized the Simulated Cell™ platform, integrating omics data with curated signaling networks.
- Performed large-scale combinatorial drug sensitivity screening across 97 cancer cell lines with 684 drug combinations.
- Employed network biology and simulation to predict combination efficacy and identify synergistic pairs.
Main Results:
- Accurately predicted 66,348 combination-cell line pairs with high performance (BAC=0.62, AUC=0.7).
- Highlighted synergistic drug combinations targeting DNA Damage Response pathways.
- Identified key biomarkers driving combination synergy through deep network analysis.
Conclusions:
- The Simulated Cell™ accurately predicts synergistic drug combinations and their underlying mechanisms.
- This approach facilitates the identification of effective combination therapies and biomarkers for clinical translation.
- Network biology-driven simulations offer a powerful strategy to navigate combinatorial drug discovery in cancer.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...